Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

13.02
-1.6100-11.00%
Post-market: 13.480.4608+3.54%19:59 EST
Volume:2.11M
Turnover:29.29M
Market Cap:72.79M
PE:-1.68
High:15.30
Open:14.60
Low:12.66
Close:14.63
Loading ...

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals

GlobeNewswire
·
08 Oct 2024

BRIEF-Tonix Pharmaceuticals Entered Into An AI And ML Research Collaboration With X-Chem

Reuters
·
08 Oct 2024

Tonix Pharmaceuticals: Entered Into an AI and Ml Research Collaboration With X-Chem, Inc

THOMSON REUTERS
·
08 Oct 2024

The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions

ACCESSWIRE
·
01 Oct 2024

Tonix Pharmaceuticals (TNXP) Has a Promising Pipeline but Faces Financial Challenges

TIPRANKS
·
01 Oct 2024

Tonix Pharmaceuticals participates in Endpoints panel at RECOVER workshop

TIPRANKS
·
30 Sep 2024

Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAID)

GlobeNewswire
·
30 Sep 2024

Tonix Pharmaceuticals Receives US Patent for Migraine Treatment; Shares Rise

MT Newswires Live
·
27 Sep 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® Symtouch® to Treat Migraines

THOMSON REUTERS
·
27 Sep 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines

GlobeNewswire
·
27 Sep 2024

BRIEF-Tonix Pharmaceuticals Holding Corp Files For Mixed Shelf Offering Of Upto $300 Million- SEC Filing

Reuters
·
21 Sep 2024

Tonix Pharmaceuticals Secures US Patent for Migraine Treatment -- Shares Rise Pre-Bell

MT Newswires Live
·
19 Sep 2024

BRIEF-Tonix Pharmaceuticals Announces Issuance Of U.S. Patent For FDA-Approved Tosymra® To Treat Migraines

Reuters
·
19 Sep 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

THOMSON REUTERS
·
19 Sep 2024

Tonix Pharmaceuticals Holding Corp: New Patent Expected to Expire in 2030

THOMSON REUTERS
·
19 Sep 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

GlobeNewswire
·
19 Sep 2024